Spero Therapeutics (SPRO) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to -$482.6 million.
- Spero Therapeutics' Retained Earnings fell 998.18% to -$482.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$482.6 million, marking a year-over-year decrease of 998.18%. This contributed to the annual value of -$459.6 million for FY2024, which is 1753.28% down from last year.
- As of Q3 2025, Spero Therapeutics' Retained Earnings stood at -$482.6 million, which was down 998.18% from -$475.2 million recorded in Q2 2025.
- In the past 5 years, Spero Therapeutics' Retained Earnings registered a high of -$297.1 million during Q1 2021, and its lowest value of -$482.6 million during Q3 2025.
- Over the past 5 years, Spero Therapeutics' median Retained Earnings value was -$427.1 million (recorded in 2023), while the average stood at -$413.5 million.
- In the last 5 years, Spero Therapeutics' Retained Earnings plummeted by 3588.76% in 2022 and then surged by 551.03% in 2023.
- Over the past 5 years, Spero Therapeutics' Retained Earnings (Quarter) stood at -$367.5 million in 2021, then fell by 12.63% to -$413.9 million in 2022, then rose by 5.51% to -$391.1 million in 2023, then fell by 17.53% to -$459.6 million in 2024, then fell by 5.0% to -$482.6 million in 2025.
- Its Retained Earnings stands at -$482.6 million for Q3 2025, versus -$475.2 million for Q2 2025 and -$473.5 million for Q1 2025.